DoW Peer Reviewed Cancer, Clinical Trial Award

Opportunity ID: 362268

This opportunity is no longer listed as open or forecasted.

General Information

Assistance Listings

• 12.420 — Military Medical Research and Development

Eligibility

Eligible Applicants

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Description

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.

Distinctive Features:

• Applications to this award mechanism must include a clinical trial.

• Projects can range from phase 0 to phase III.

• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.

• Applications are required to include patient advocates.

• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

Additional Information

Contact	Abigail Strock Contract Specialist
Contact Information	eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Email	help@eBRAP.org
Email Description	eBRAP Help Desk
Phone	3016192342

Additional information

Version History

Id	362268
Revision	0
Opportunity number	HT942526PRCRPCTA
Opportunity title	DoW Peer Reviewed Cancer, Clinical Trial Award
Owning agency code	DOD-AMRAA
Opportunity category / Category	D
Opportunity category / Description	Discretionary
Synopsis / Opportunity id	362268
Synopsis / Version	1
Synopsis / Agency code	DOD-AMRAA
Synopsis / Agency name	Abigail Strock Contract Specialist
Synopsis / Agency phone	3016192342
Synopsis / Agency address desc	eBRAP Help Desk
Synopsis / Agency details / Code	AMRAA
Synopsis / Agency details / Seed	DOD-AMRAA
Synopsis / Agency details / Agency name	Defense Health Agency Contracting Activity – DHACA
Synopsis / Agency details / Agency code	DOD-AMRAA
Synopsis / Agency details / Top agency code	DOD
Synopsis / Top agency details / Code	DOD
Synopsis / Top agency details / Seed	DOD
Synopsis / Top agency details / Agency name	Department of Defense
Synopsis / Top agency details / Agency code	DOD
Synopsis / Top agency details / Top agency code	DOD
Synopsis / Agency contact phone	3016192342
Synopsis / Agency contact name	Abigail Strock Contract Specialist
Synopsis / Agency contact desc	eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Synopsis / Agency contact email	help@eBRAP.org
Synopsis / Agency contact email desc	eBRAP Help Desk
Synopsis / Synopsis desc	Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. • Applications are required to include patient advocates. • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.
Synopsis / Response date	Oct 05, 2026 12:00:00 AM EDT
Synopsis / Response date desc	Not specified
Synopsis / Posting date	May 06, 2026 12:00:00 AM EDT
Synopsis / Archive date	Nov 04, 2026 12:00:00 AM EST
Synopsis / Cost sharing	No
Synopsis / Number of awards	10
Synopsis / Estimated funding	45000000
Synopsis / Estimated funding formatted	45,000,000
Synopsis / Award ceiling	none
Synopsis / Award floor	none
Synopsis / Applicant eligibility desc	Not specified
Synopsis / Create time stamp	May 06, 2026 10:39:45 AM EDT
Synopsis / Created date	May 06, 2026 10:37:42 AM EDT
Synopsis / Last updated date	May 06, 2026 10:37:42 AM EDT
Synopsis / Applicant types 1 / Id	99
Synopsis / Applicant types 1 / Description	Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Synopsis / Funding instruments 1 / Id	G
Synopsis / Funding instruments 1 / Description	Grant
Synopsis / Funding activity categories 1 / Id	ST
Synopsis / Funding activity categories 1 / Description	Science and Technology and other Research and Development
Synopsis / Response date str	2026-10-05-00-00-00
Synopsis / Posting date str	2026-05-06-00-00-00
Synopsis / Archive date str	2026-11-04-00-00-00
Synopsis / Create time stamp str	2026-05-06-10-39-45
Agency details / Code	AMRAA
Agency details / Seed	DOD-AMRAA
Agency details / Agency name	Defense Health Agency Contracting Activity – DHACA
Agency details / Agency code	DOD-AMRAA
Agency details / Top agency code	DOD
Top agency details / Code	DOD
Top agency details / Seed	DOD
Top agency details / Agency name	Department of Defense
Top agency details / Agency code	DOD
Top agency details / Top agency code	DOD
Synopsis attachment folders 1 / Id	79605
Synopsis attachment folders 1 / Opportunity id	362268
Synopsis attachment folders 1 / Folder type	Full Announcement
Synopsis attachment folders 1 / Folder name	FY26 PRCRP CTA
Synopsis attachment folders 1 / Zip lob size	694116
Synopsis attachment folders 1 / Created date	May 06, 2026 10:38:02 AM EDT
Synopsis attachment folders 1 / Last updated date	May 06, 2026 10:39:45 AM EDT
Synopsis attachment folders 1 / Synopsis attachments 1 / Id	351813
Synopsis attachment folders 1 / Synopsis attachments 1 / Opportunity id	362268
Synopsis attachment folders 1 / Synopsis attachments 1 / Mime type	application/pdf
Synopsis attachment folders 1 / Synopsis attachments 1 / File name	HT942526PRCRPCTA_GG.pdf
Synopsis attachment folders 1 / Synopsis attachments 1 / File description	FY26 PRCRP CTA Program Announcement
Synopsis attachment folders 1 / Synopsis attachments 1 / File lob size	886978
Synopsis attachment folders 1 / Synopsis attachments 1 / Created date	May 06, 2026 10:39:45 AM EDT
Synopsis attachment folders 1 / Synopsis attachments 1 / Synopsis att folder id	79605
Synopsis document urls	Not specified
Syn att change comments	Not specified
Cfdas 1 / Id	433173
Cfdas 1 / Opportunity id	362268
Cfdas 1 / Cfda number	12.420
Cfdas 1 / Program title	Military Medical Research and Development
Opportunity pkgs	Not specified
Closed opportunity pkgs 1 / Id	292694
Closed opportunity pkgs 1 / Topportunity id	362268
Closed opportunity pkgs 1 / Family id	14
Closed opportunity pkgs 1 / Dialect	XFDL2.2
Closed opportunity pkgs 1 / Opportunity number	HT942526PRCRPCTA
Closed opportunity pkgs 1 / Opportunity title	DoW Peer Reviewed Cancer, Clinical Trial Award
Closed opportunity pkgs 1 / Cfda number	12.420
Closed opportunity pkgs 1 / Opening date	May 06, 2026 12:00:00 AM EDT
Closed opportunity pkgs 1 / Closing date	Oct 05, 2026 12:00:00 AM EDT
Closed opportunity pkgs 1 / Owning agency code	DOD-AMRAA
Closed opportunity pkgs 1 / Program title	Military Medical Research and Development
Closed opportunity pkgs 1 / Contact info	eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Closed opportunity pkgs 1 / Grace period	0
Closed opportunity pkgs 1 / Electronic required	Y
Closed opportunity pkgs 1 / Expected application count	100
Closed opportunity pkgs 1 / Expected application size	1000000
Closed opportunity pkgs 1 / Open to applicant type	1
Closed opportunity pkgs 1 / Is multi project	N
Closed opportunity pkgs 1 / Extension	pdf
Closed opportunity pkgs 1 / Mimetype	application/pdf
Closed opportunity pkgs 1 / Last update	May 06, 2026 10:40:40 AM EDT
Closed opportunity pkgs 1 / Workspace compatible flag	Y
Closed opportunity pkgs 1 / Package id	PKG00292694
Closed opportunity pkgs 1 / Opening date str	2026-05-06-00-00-00
Closed opportunity pkgs 1 / Closing date str	2026-10-05-00-00-00
Original due date	Oct 05, 2026 12:00:00 AM EDT
Original due date desc	Not specified
Synopsis modified fields	Not specified
Forecast modified fields	Not specified
Error messages	Not specified
Syn post date in past	Yes
Doc type	synopsis
Forecast hist count	0
Synopsis hist count	0
Assist compatible	No
Assist url	Not specified
Related opps	Not specified
Ost	CLOSED

Related Documents

Packages

Agency Contact Information:

eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

Package 1

Instructions

Mandatory forms

Optional forms